glp-1 agonist drug interactions Advances in receptor agonists: Molecular mechanisms, delivery innovations, formulation strategies, and emerging therapeutic applications A schematic overview of GLP-1

This loss is not merely a cosmetic inconvenience

Wegovy, Zepbound, and Saxenda are currently the only GLP-1 agonists approved as weight loss drugs

As individuals seek solutions to combat obesity, medications like Wegovy and Mounjaro have gained popularity

while the EULAR Points to Consider provide valuable guidance, the development of standardized criteria will be essential to advance research in this area

Dietary and lifestyle modifications: Patients benefit from specific guidance regarding eating patterns and food choices: Smaller, more frequent meals Consuming 5-6 small meals rather than 3 large meals reduces gastric distension Slower eating pace Taking 20-30 minutes per meal and chewing thoroughly Avoiding high-fat foods Fatty meals delay gastric emptying further and may exacerbate symptoms Limiting very high-fiber foods During symptomatic periods, as these can worsen bloating Limiting carbonated beverages Reducing bloating and distension Adequate hydration Maintaining fluid intake between meals rather than with meals Remaining upright after eating Avoiding recumbent positions for 2-3 hours post-meal Symptomatic management: When lifestyle modifications prove insufficient, pharmacological interventions may provide relief